Jill Schwartz-Gomez

机构：The University of Texas MD Anderson Cancer Center

发表论文 6 篇 · 总被引 277 次 · h-index 5

代表论文

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant (2019 · Journal of Clinical Oncology · 被引 197)
Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). (2018 · Journal of Clinical Oncology · 被引 33)
Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study (2022 · Cancer Research · 被引 27)
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. (2024 · Journal of Clinical Oncology · 被引 12)
A feasibility study of neoadjuvant talazoparib for early-stage breast cancer patients with a germline BRCA pathogenic variant: NCT02282345. (2017 · Journal of Clinical Oncology · 被引 7)
Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results (2026 · Nature Cancer · 被引 1)